Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-09-08
DOI
10.3389/fendo.2021.735019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and characterization of a surfactant‐conjugated, long‐acting, balanced GLP ‐1/glucagon receptor dual agonist
- (2021) John J. Nestor et al. Peptide Science
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Centrality of Obesity in the Course of Severe COVID-19
- (2021) Danfei Liu et al. Frontiers in Endocrinology
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)
- (2020) Chen Cheng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships
- (2020) Barry M. Popkin et al. Obesity Reviews
- Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
- (2020) Olof Eriksson et al. Scientific Reports
- Obesity: global epidemiology and pathogenesis
- (2019) Matthias Blüher Nature Reviews Endocrinology
- Glucagon Receptor Signaling and Lipid Metabolism
- (2019) Katrine D. Galsgaard et al. Frontiers in Physiology
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist
- (2019) Victoria E R Parker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MEDI0382, a GLP-1-glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomised, phase 1 study
- (2018) Philip D. Ambery et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
- (2018) Sofie Hædersdal et al. MAYO CLINIC PROCEEDINGS
- Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
- (2018) R. Scott et al. PEPTIDES
- Hepatic Glucagon-Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents
- (2018) Teayoun Kim et al. DIABETES
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
- (2017) Andreas Evers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Bariatric Surgery and Long-term Durability of Weight Loss
- (2016) Matthew L. Maciejewski et al. JAMA Surgery
- Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
- (2016) Nicolai J. Wewer Albrechtsen et al. EBioMedicine
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
- (2015) Jonatan Ising Bagger et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
- (2014) Jaimini Cegla et al. DIABETES
- A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity
- (2013) Elisabetta Bianchi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
- (2013) K. M. Habegger et al. DIABETES
- Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala
- (2013) J A Parker et al. INTERNATIONAL JOURNAL OF OBESITY
- Action and therapeutic potential of oxyntomodulin
- (2013) Alessandro Pocai Molecular Metabolism
- Differential effects of oxyntomodulin and GLP-1 on glucose metabolism
- (2012) Xiaobing Du et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
- (2012) T. M. Tan et al. DIABETES
- The Glucagon Receptor Is Involved in Mediating the Body Weight-Lowering Effects of Oxyntomodulin
- (2012) Jennifer R. Kosinski et al. Obesity
- Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
- (2011) Philip E. Cryer ENDOCRINOLOGY
- DPP-IV-resistant, long-acting oxyntomodulin derivatives
- (2011) Alessia Santoprete et al. JOURNAL OF PEPTIDE SCIENCE
- (d-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
- (2010) Barry D. Kerr et al. BIOCHEMICAL PHARMACOLOGY
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
- (2008) Maralyn R. Druce et al. ENDOCRINOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started